We	O
report	O
here	O
on	O
a	O
patient	B
who	O
was	O
treated	O
for	O
an	O
atypical	O
brain	O
meningioma	O
with	O
multiple	O
surgeries	O
and	O
multiple	O
sessions	O
of	O
stereotactic	O
radiosurgery	O
with	O
good	O
control	O
of	O
his	O
brain	O
disease	O
.	O

Thirteen	O
years	O
after	O
diagnosis	O
,	O
he	O
developed	O
bilateral	O
large	O
sacroiliac	O
and	O
abdominal	O
metastases	O
.	O

Extracranial	O
metastases	O
from	O
brain	O
meningiomas	O
is	O
a	O
rare	O
,	O
but	O
well	O
-	O
documented	O
entity	O
.	O

Metastases	O
occur	O
mostly	O
in	O
the	O
lungs	O
,	O
pleura	O
and	O
liver	O
,	O
but	O
may	O
also	O
affect	O
lymph	O
nodes	O
and	O
bones	O
.	O

Extraneural	O
metastases	O
from	O
cranial	O
meningioma	O
:	O
a	O
case	O
report	O
.	O

Here	O
we	O
expand	O
the	O
role	O
of	O
GRN	O
in	O
FTLD	O
-	O
U	O
and	O
demonstrate	O
that	O
a	O
common	O
genetic	O
variant	O
(	O
rs5848	O
)	O
,	O
located	O
in	O
the	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
GRN	O
in	O
a	O
binding	O
-	O
site	O
for	O
miR-659	O
,	O
is	O
a	O
major	O
susceptibility	O
factor	O
for	O
FTLD	O
-	O
U.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
progranulin	O
(	O
GRN	O
)	O
cause	O
ubiquitin-	O
and	O
TAR	O
DNA	O
-	O
binding	O
protein	O
43	O
(	O
TDP-43	O
)	O
-positive	O
frontotemporal	O
dementia	O
(	O
FTLD	O
-	O
U	O
)	O
,	O
a	O
progressive	O
neurodegenerative	O
disease	O
affecting	O
approximately	O
10	O
%	O
of	O
early	O
-	O
onset	O
dementia	O
patients	B
.	O

Common	O
variation	O
in	O
the	O
miR-659	O
binding	O
-	O
site	O
of	O
GRN	O
is	O
a	O
major	O
risk	O
factor	O
for	O
TDP43-positive	O
frontotemporal	O
dementia	O
.	O

In	O
support	O
of	O
these	O
findings	O
,	O
the	O
neuropathology	O
of	O
homozygous	O
rs5848	O
T	O
-	O
allele	O
carriers	O
frequently	O
resembled	O
the	O
pathological	O
FTLD	O
-	O
U	O
subtype	O
of	O
GRN	O
mutation	O
carriers	O
.	O

A	O
significant	O
reduction	O
in	O
GRN	O
protein	O
was	O
observed	O
in	O
homozygous	O
T	O
-	O
allele	O
carriers	O
in	O
vivo	O
,	O
through	O
biochemical	O
and	O
immunohistochemical	O
methods	O
,	O
mimicking	O
the	O
effect	O
of	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
GRN	O
mutations	O
.	O

We	O
further	O
demonstrate	O
that	O
miR-659	O
can	O
regulate	O
GRN	O
expression	O
in	O
vitro	O
,	O
with	O
miR-659	O
binding	O
more	O
efficiently	O
to	O
the	O
high	O
risk	O
T	O
-	O
allele	O
of	O
rs5848	O
resulting	O
in	O
augmented	O
translational	O
inhibition	O
of	O
GRN	O
.	O

In	O
a	O
series	O
of	O
pathologically	O
confirmed	O
FTLD	O
-	O
U	O
patients	B
without	O
GRN	O
mutations	O
,	O
we	O
show	O
that	O
carriers	O
homozygous	O
for	O
the	O
T	O
-	O
allele	O
of	O
rs5848	O
have	O
a	O
3.2-fold	O
increased	O
risk	O
to	O
develop	O
FTLD	O
-	O
U	O
compared	O
with	O
homozygous	O
C	O
-	O
allele	O
carriers	O
(	O
95	O
%	O
CI	O
:	O
1.50	O
-	O
6.73	O
)	O
.	O

Translational	O
regulation	O
by	O
miRNAs	O
may	O
represent	O
a	O
common	O
mechanism	O
underlying	O
complex	O
neurodegenerative	O
disorders	O
.	O

We	O
suggest	O
that	O
the	O
expression	O
of	O
GRN	O
is	O
regulated	O
by	O
miRNAs	O
and	O
that	O
common	O
genetic	O
variability	O
in	O
a	O
miRNA	O
binding	O
-	O
site	O
can	O
significantly	O
increase	O
the	O
risk	O
for	O
FTLD	O
-	O
U.	O

Here	O
,	O
we	O
discuss	O
recent	O
data	O
that	O
support	O
a	O
view	O
that	O
endolysosomal	O
positioning	O
of	O
RNA	O
might	O
facilitate	O
intercellular	O
transmission	O
of	O
RNA	O
and	O
host	O
defence	O
against	O
viruses	O
and	O
retrotransposons	O
.	O

Positioning	O
of	O
RNA	O
regulatory	O
mechanisms	O
on	O
endolysosomal	O
membranes	O
might	O
permit	O
rapid	O
and	O
localized	O
control	O
of	O
microRNA	O
(	O
miRNA	O
)	O
gene	O
regulatory	O
programs	O
and	O
mRNA	O
translation	O
in	O
response	O
to	O
environmental	O
signals	O
,	O
such	O
as	O
activated	O
plasma	O
membrane	O
receptors	O
transported	O
on	O
endosomes	O
.	O

Finally	O
,	O
we	O
suggest	O
that	O
the	O
pathology	O
of	O
several	O
conditions	O
,	O
including	O
Huntington	O
's	O
disease	O
,	O
might	O
be	O
a	O
consequence	O
of	O
the	O
disruption	O
of	O
the	O
control	O
of	O
RNA	O
via	O
endolysosomal	O
membranes	O
.	O

Control	O
of	O
RNA	O
silencing	O
and	O
localization	O
by	O
endolysosomes	O
.	O

Recent	O
advances	O
in	O
the	O
cell	O
biology	O
of	O
RNA	O
silencing	O
have	O
unraveled	O
an	O
intriguing	O
association	O
of	O
post	O
-	O
transcriptionally	O
regulated	O
RNA	O
with	O
endolysosomal	O
membranes	O
in	O
several	O
circumstances	O
of	O
mRNA	O
localization	O
,	O
microRNA	O
activity	O
and	O
viral	O
RNA	O
transport	O
and	O
packaging	O
.	O

Endolysosomal	O
membranes	O
are	O
a	O
nexus	O
of	O
communication	O
and	O
transport	O
between	O
cells	O
and	O
their	O
exterior	O
environment	O
for	O
signaling	O
receptors	O
,	O
pathogens	O
and	O
nutrients	O
.	O

The	O
method	O
by	O
which	O
MSCs	O
could	O
be	O
applied	O
for	O
future	O
therapies	O
might	O
require	O
trans	O
-	O
disciplinary	O
approaches	O
for	O
personalized	O
treatments	O
.	O

Implantation	O
of	O
adult	O
human	B
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
to	O
treat	O
neural	O
disorders	O
shows	O
promise	O
.	O

Depending	O
on	O
their	O
microenvironment	O
,	O
MSCs	O
could	O
potentially	O
be	O
used	O
for	O
the	O
repair	O
and/or	O
replacement	O
of	O
neurons	O
in	O
traumatic	O
brain	O
injury	O
or	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

This	O
cross	O
-	O
disciplinary	O
review	O
incorporates	O
aspects	O
of	O
neuroscience	O
,	O
stem	O
cell	O
biology	O
,	O
cancer	O
biology	O
and	O
immunology	O
to	O
discuss	O
interactions	O
between	O
inflammatory	O
mediators	O
and	O
MSCs	O
.	O

We	O
first	O
discuss	O
the	O
role	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
neurological	O
development	O
.	O

Neurogenesis	O
:	O
role	O
for	O
microRNAs	O
and	O
mesenchymal	O
stem	O
cells	O
in	O
pathological	O
states	O
.	O

Exploring	O
the	O
predisposition	O
of	O
MSCs	O
to	O
oncogenesis	O
is	O
critical	O
for	O
translational	O
science	O
since	O
the	O
implementation	O
of	O
safeguarding	O
measures	O
prior	O
to	O
therapy	O
can	O
lead	O
to	O
the	O
successful	O
delivery	O
of	O
stem	O
cells	O
to	O
patients	B
.	O

The	O
administration	O
of	O
effective	O
and	O
safe	O
MSC	O
therapy	O
must	O
acknowledge	O
immune	O
mediators	O
that	O
may	O
predispose	O
the	O
early	O
differentiating	O
MSCs	O
to	O
oncogenic	O
insults	O
.	O

Secondly	O
,	O
we	O
discuss	O
the	O
ability	O
of	O
MSCs	O
to	O
transdifferentiate	O
into	O
functional	O
neurons	O
,	O
which	O
are	O
regulated	O
by	O
miRNAs	O
,	O
and	O
the	O
implications	O
of	O
these	O
cells	O
for	O
the	O
therapy	O
of	O
neuropathological	O
states	O
.	O

Immune	O
mediators	O
could	O
be	O
central	O
to	O
MSC	O
responses	O
within	O
a	O
region	O
of	O
tissue	O
injury	O
and	O
are	O
also	O
discussed	O
in	O
detail	O
.	O

Thus	O
,	O
we	O
discuss	O
a	O
key	O
gene	O
,	O
RE-1	O
silencing	O
transcription	O
factor	O
(	O
REST	O
)	O
,	O
based	O
on	O
its	O
dual	O
role	O
in	O
neurogenesis	O
and	O
cancer	O
development	O
.	O

Finally	O
,	O
a	O
phylogenetic	O
analysis	O
shows	O
that	O
ADCK3	O
belongs	O
to	O
the	O
family	O
of	O
atypical	O
kinases	O
,	O
which	O
includes	O
phosphoinositide	O
and	O
choline	O
kinases	O
,	O
suggesting	O
that	O
ADCK3	O
plays	O
an	O
indirect	O
regulatory	O
role	O
in	O
ubiquinone	O
biosynthesis	O
possibly	O
as	O
part	O
of	O
a	O
feedback	O
loop	O
that	O
regulates	O
ATP	O
production	O
.	O

ADCK3	O
,	O
an	O
ancestral	O
kinase	O
,	O
is	O
mutated	O
in	O
a	O
form	O
of	O
recessive	O
ataxia	O
associated	O
with	O
coenzyme	O
Q10	O
deficiency	O
.	O

Muscle	O
coenzyme	O
Q	O
(	O
10	O
)	O
(	O
CoQ	O
(	O
10	O
)	O
or	O
ubiquinone	O
)	O
deficiency	O
has	O
been	O
identified	O
in	O
more	O
than	O
20	O
patients	B
with	O
presumed	O
autosomal	O
-	O
recessive	O
ataxia	O
.	O

However	O
,	O
mutations	O
in	O
genes	O
required	O
for	O
CoQ	O
(	O
10	O
)	O
biosynthetic	O
pathway	O
have	O
been	O
identified	O
only	O
in	O
patients	B
with	O
infantile	O
-	O
onset	O
multisystemic	O
diseases	O
or	O
isolated	O
nephropathy	O
.	O

Our	O
SNP	O
-	O
based	O
genome	O
-	O
wide	O
scan	O
in	O
a	O
large	O
consanguineous	O
family	O
revealed	O
a	O
locus	O
for	O
autosomal	O
-	O
recessive	O
ataxia	O
at	O
chromosome	O
1q41	O
.	O

The	O
causative	O
mutation	O
is	O
a	O
homozygous	O
splice	O
-	O
site	O
mutation	O
in	O
the	O
aarF	O
-	O
domain	O
-	O
containing	O
kinase	O
3	O
gene	O
(	O
ADCK3	O
)	O
.	O

Five	O
additional	O
mutations	O
in	O
ADCK3	O
were	O
found	O
in	O
three	O
patients	B
with	O
sporadic	O
ataxia	O
,	O
including	O
one	O
known	O
to	O
have	O
CoQ	O
(	O
10	O
)	O
deficiency	O
in	O
muscle	O
.	O

All	O
of	O
the	O
patients	B
have	O
childhood	O
-	O
onset	O
cerebellar	O
ataxia	O
with	O
slow	O
progression	O
,	O
and	O
three	O
of	O
six	O
have	O
mildly	O
elevated	O
lactate	O
levels	O
.	O

ADCK3	O
is	O
a	O
mitochondrial	O
protein	O
homologous	O
to	O
the	O
yeast	O
COQ8	O
and	O
the	O
bacterial	O
UbiB	O
proteins	O
,	O
which	O
are	O
required	O
for	O
CoQ	O
biosynthesis	O
.	O

Three	O
out	O
of	O
four	O
patients	B
tested	O
showed	O
a	O
low	O
endogenous	O
pool	O
of	O
CoQ	O
(	O
10	O
)	O
in	O
their	O
fibroblasts	O
or	O
lymphoblasts	O
,	O
and	O
two	O
out	O
of	O
three	O
patients	B
showed	O
impaired	O
ubiquinone	O
synthesis	O
,	O
strongly	O
suggesting	O
that	O
ADCK3	O
is	O
also	O
involved	O
in	O
CoQ	O
(	O
10	O
)	O
biosynthesis	O
.	O

The	O
deleterious	O
nature	O
of	O
the	O
three	O
identified	O
missense	O
changes	O
was	O
confirmed	O
by	O
the	O
introduction	O
of	O
them	O
at	O
the	O
corresponding	O
positions	O
of	O
the	O
yeast	O
COQ8	O
gene	O
.	O

Interpretation	O
and	O
applicability	O
of	O
microRNA	O
data	O
to	O
the	O
context	O
of	O
Alzheimer	O
's	O
and	O
age	O
-	O
related	O
diseases	O
.	O

Generated	O
by	O
the	O
ribonuclease	O
III	O
Dicer	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
predicted	O
to	O
regulate	O
up	O
to	O
90	O
%	O
of	O
the	O
genes	O
in	O
humans	B
,	O
suggesting	O
that	O
they	O
may	O
control	O
every	O
cellular	O
processes	O
in	O
all	O
cells	O
and	O
tissues	O
of	O
the	O
human	B
body	O
!	O

Likely	O
to	O
play	O
a	O
central	O
role	O
in	O
health	O
and	O
disease	O
,	O
a	O
dysfunctional	O
miRNA	O
-	O
based	O
regulation	O
of	O
gene	O
expression	O
may	O
represent	O
the	O
main	O
etiologic	O
factor	O
underlying	O
age	O
-	O
related	O
diseases	O
affecting	O
major	O
organs	O
,	O
such	O
as	O
the	O
brain	O
.	O

Here	O
,	O
we	O
discuss	O
some	O
of	O
the	O
limitations	O
associated	O
to	O
the	O
interpretation	O
and	O
applicability	O
of	O
miRNA	O
data	O
,	O
based	O
on	O
our	O
recent	O
study	O
on	O
the	O
etiology	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Using	O
transiently	O
transfected	O
murine	B
neuronal	O
N2a	O
cells	O
in	O
culture	O
,	O
in	O
parallel	O
to	O
a	O
mouse	B
model	O
of	O
AD	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
a	O
role	O
for	O
two	O
miRNAs	O
(	O
miR-298	O
and	O
miR-328	O
)	O
in	O
the	O
regulation	O
of	O
beta	O
-	O
amyloid	O
(	O
Abeta	O
)	O
precursor	O
protein	O
(	O
APP	O
)	O
-converting	O
enzyme	O
(	O
BACE	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
translation	O
,	O
thereby	O
providing	O
key	O
insights	O
into	O
the	O
molecular	O
basis	O
underlying	O
BACE	O
deregulation	O
in	O
AD	O
.	O

However	O
,	O
whether	O
miRNA	O
data	O
can	O
be	O
extrapolated	O
and	O
transposed	O
to	O
the	O
human	B
context	O
of	O
age	O
-	O
related	O
diseases	O
,	O
such	O
as	O
AD	O
,	O
not	O
only	O
requires	O
caution	O
,	O
but	O
also	O
warrants	O
several	O
considerations	O
.	O

Levels	O
of	O
protein	O
expression	O
of	O
endothelial	O
NO	O
synthase	O
(	O
eNOS	O
)	O
,	O
caveolin-1	O
,	O
and	O
calmodulin	O
were	O
assessed	O
in	O
carotid	O
arteries	O
using	O
Western	O
analysis	O
.	O

Plasma	O
NO	O
levels	O
were	O
doubled	O
by	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

NO	O
production	O
and	O
endothelium	O
-	O
dependent	O
contraction	O
in	O
response	O
to	O
the	O
NOS	O
inhibitor	O
NG	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
(	O
L	O
-	O
NNA	O
;	O
100	O
microM	O
)	O
was	O
enhanced	O
by	O
50	O
to	O
100	O
%	O
in	O
carotid	O
arteries	O
from	O
rats	B
treated	O
with	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

Acetylcholine	O
-	O
induced	O
relaxation	O
was	O
selectively	O
enhanced	O
in	O
carotid	O
arteries	O
from	O
rats	B
treated	O
with	O
daidzein	O
.	O

The	O
use	O
of	O
estrogen	O
for	O
protection	O
against	O
vascular	O
dysfunction	O
is	O
limited	O
due	O
to	O
its	O
effects	O
on	O
the	O
reproductive	O
system	O
,	O
particularly	O
in	O
males	O
.	O

We	O
postulated	O
that	O
daidzein	O
,	O
an	O
isoflavone	O
with	O
estrogen	O
-	O
like	O
effects	O
on	O
the	O
systemic	O
vasculature	O
but	O
not	O
the	O
reproductive	O
system	O
,	O
might	O
enhance	O
nitric	O
oxide	O
(	O
NO	O
)	O
-mediated	O
cerebral	O
vasodilatation	O
.	O

Male	O
rats	B
were	O
administered	O
vehicle	O
,	O
17beta	O
-	O
estradiol	O
(	O
0.1	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
,	O
or	O
daidzein	O
(	O
0.2	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
daily	O
for	O
7	O
days	O
.	O

Basal	O
and	O
acetylcholine	O
-	O
stimulated	O
NO	O
release	O
was	O
assessed	O
in	O
vitro	O
via	O
carotid	O
arterial	O
rings	O
or	O
in	O
vivo	O
by	O
measuring	O
changes	O
in	O
basilar	O
artery	O
diameter	O
.	O

Similarly	O
,	O
constrictor	O
responses	O
of	O
the	O
basilar	O
artery	O
to	O
L	O
-	O
NNA	O
in	O
vivo	O
were	O
selectively	O
augmented	O
by	O
approximately	O
100	O
%	O
by	O
17beta	O
-	O
estradiol	O
treatment	O
and	O
tended	O
to	O
be	O
approximately	O
50	O
%	O
greater	O
in	O
daidzein	O
-	O
treated	O
rats	B
.	O

Effect	O
of	O
short	O
-	O
term	O
phytoestrogen	O
treatment	O
in	O
male	O
rats	B
on	O
nitric	O
oxide	O
-	O
mediated	O
responses	O
of	O
carotid	O
and	O
cerebral	O
arteries	O
:	O
comparison	O
with	O
17beta	O
-	O
estradiol	O
.	O

These	O
data	O
suggest	O
that	O
short	O
-	O
term	O
administration	O
of	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
modulates	O
cerebral	O
artery	O
reactivity	O
in	O
males	O
by	O
enhancing	O
synthesis	O
and	O
release	O
of	O
endothelium	O
-	O
derived	O
NO	O
.	O
Isoflavone	O
therapy	O
may	O
therefore	O
be	O
a	O
feasible	O
approach	O
to	O
protect	O
against	O
cerebrovascular	O
disease	O
and	O
stroke	O
.	O

Expression	O
of	O
caveolin-1	O
was	O
decreased	O
,	O
and	O
calmodulin	O
was	O
increased	O
,	O
in	O
vessels	O
from	O
daidzein-	O
or	O
17beta	O
-	O
estradiol	O
-	O
treated	O
rats	B
.	O

eNOS	O
expression	O
was	O
unaffected	O
by	O
the	O
treatments	O
.	O

However	O
,	O
we	O
report	O
the	O
experience	O
of	O
a	O
patient	B
who	O
inadvertently	O
received	O
live	O
polio	O
vaccine	O
whilst	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
.	O

International	O
guidelines	O
state	O
that	O
live	O
vaccines	O
are	O
contraindicated	O
in	O
patients	B
on	O
anti	O
-	O
TNF	O
therapy	O
.	O

Live	O
polio	O
vaccine	O
exposure	O
while	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
for	O
reactive	O
arthritis	O
.	O

Patients	B
should	O
be	O
counseled	O
regarding	O
the	O
risks	O
of	O
live	O
vaccines	O
prior	O
to	O
treatment	O
with	O
anti	O
-	O
TNF	O
therapy	O
.	O

However	O
,	O
if	O
we	O
consider	O
adult	O
patients	B
with	O
rheumatic	O
diseases	O
to	O
have	O
altered	O
immunocompetence	O
,	O
it	O
is	O
recommended	O
that	O
they	O
receive	O
the	O
usual	O
inactivated	O
vaccines	O
according	O
to	O
standard	O
schedules	O
,	O
and	O
live	O
vaccines	O
should	O
be	O
avoided	O
in	O
those	O
who	O
are	O
treated	O
with	O
more	O
potent	O
forms	O
of	O
immune	O
suppression	O
.	O

No	O
clear	O
guidelines	O
are	O
available	O
for	O
all	O
vaccines	O
in	O
patients	B
with	O
specific	O
rheumatic	O
diseases	O
.	O

Patient	B
did	O
not	O
suffer	O
from	O
any	O
infectious	O
sequel	O
as	O
a	O
result	O
.	O

Autosomal	O
-	O
recessive	O
cerebellar	O
ataxias	O
comprise	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	O
disorders	O
.	O

In	O
contrast	O
to	O
their	O
dominant	O
counterparts	O
,	O
unraveling	O
the	O
molecular	O
background	O
of	O
these	O
ataxias	O
has	O
proven	O
to	O
be	O
more	O
complicated	O
and	O
the	O
currently	O
known	O
mutations	O
provide	O
incomplete	O
coverage	O
for	O
genotyping	O
of	O
patients	B
.	O

By	O
combining	O
SNP	O
array	O
-	O
based	O
linkage	O
analysis	O
and	O
targeted	O
resequencing	O
of	O
relevant	O
sequences	O
in	O
the	O
linkage	O
interval	O
with	O
the	O
use	O
of	O
next	O
-	O
generation	O
sequencing	O
technology	O
,	O
we	O
identified	O
a	O
mutation	O
in	O
a	O
gene	O
and	O
have	O
shown	O
its	O
association	O
with	O
autosomal	O
-	O
recessive	O
cerebellar	O
ataxia	O
.	O

In	O
a	O
Dutch	O
consanguineous	O
family	O
with	O
three	O
affected	O
siblings	O
a	O
homozygous	O
12.5	O
Mb	O
region	O
on	O
chromosome	O
3	O
was	O
targeted	O
by	O
array	O
-	O
based	O
sequence	O
capture	O
.	O

Targeted	O
next	O
-	O
generation	O
sequencing	O
of	O
a	O
12.5	O
Mb	O
homozygous	O
region	O
reveals	O
ANO10	O
mutations	O
in	O
patients	B
with	O
autosomal	O
-	O
recessive	O
cerebellar	O
ataxia	O
.	O

The	O
analysis	O
of	O
ANO10	O
by	O
Sanger	O
sequencing	O
revealed	O
three	O
additional	O
mutations	O
:	O
a	O
homozygous	O
mutation	O
(	O
c.1150_1151del	O
[	O
p	O
.	O
Leu384fs	O
]	O
)	O
in	O
a	O
Serbian	O
family	O
and	O
a	O
compound	O
-	O
heterozygous	O
splice	O
-	O
site	O
mutation	O
(	O
c.1476	O
+	O
1G	O
>	O
T	O
)	O
and	O
a	O
frameshift	O
mutation	O
(	O
c.1604del	O
[	O
p	O
.	O
Leu535X	O
]	O
)	O
in	O
a	O
French	O
family	O
.	O

This	O
illustrates	O
the	O
power	O
of	O
using	O
initial	O
homozygosity	O
mapping	O
with	O
next	O
-	O
generation	O
sequencing	O
technology	O
to	O
identify	O
genes	O
involved	O
in	O
autosomal	O
-	O
recessive	O
diseases	O
.	O

Prioritization	O
of	O
all	O
detected	O
sequence	O
variants	O
led	O
to	O
four	O
candidate	O
genes	O
,	O
one	O
of	O
which	O
contained	O
a	O
variant	O
with	O
a	O
high	O
base	O
pair	O
conservation	O
score	O
(	O
phyloP	O
score	O
:	O
5.26	O
)	O
.	O

This	O
variant	O
was	O
a	O
leucine	O
-	O
to	O
-	O
arginine	O
substitution	O
in	O
the	O
DUF	O
590	O
domain	O
of	O
a	O
16	O
K	O
transmembrane	O
protein	O
,	O
a	O
putative	O
calcium	O
-	O
activated	O
chloride	O
channel	O
encoded	O
by	O
anoctamin	O
10	O
(	O
ANO10	O
)	O
.	O

Moreover	O
,	O
identifying	O
a	O
putative	O
calcium	O
-	O
dependent	O
chloride	O
channel	O
involved	O
in	O
cerebellar	O
ataxia	O
adds	O
another	O
pathway	O
to	O
the	O
list	O
of	O
pathophysiological	O
mechanisms	O
that	O
may	O
cause	O
cerebellar	O
ataxia	O
.	O

These	O
findings	O
further	O
support	O
the	O
idea	O
that	O
iron-	O
and	O
aluminum	O
-	O
sulfates	O
induce	O
genotoxicity	O
via	O
a	O
ROS	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
specific	O
regulatory	O
elements	O
and	O
pathogenic	O
genes	O
that	O
redirect	O
brain	O
cell	O
fate	O
towards	O
progressive	O
dysfunction	O
and	O
apoptotic	O
cell	O
death	O
.	O

Notably	O
,	O
these	O
same	O
miRNAs	O
are	O
up	O
-	O
regulated	O
in	O
AD	O
brain	O
.	O

The	O
main	O
finding	O
was	O
that	O
these	O
ROS	O
-	O
generating	O
neurotoxic	O
metal	O
sulfates	O
also	O
up	O
-	O
regulate	O
a	O
specific	O
set	O
of	O
miRNAs	O
that	O
includes	O
miR-9	O
,	O
miR-125b	O
and	O
miR-128	O
.	O

In	O
this	O
study	O
we	O
have	O
extended	O
our	O
investigations	O
to	O
analyze	O
the	O
expression	O
of	O
micro	O
RNA	O
(	O
miRNA	O
)	O
populations	O
in	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
treated	O
human	B
neural	O
cells	O
in	O
primary	O
culture	O
.	O

Notably	O
,	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
induce	O
genes	O
in	O
cultured	O
human	B
brain	O
cells	O
that	O
exhibit	O
expression	O
patterns	O
similar	O
to	O
those	O
observed	O
to	O
be	O
up	O
-	O
regulated	O
in	O
moderate-	O
to	O
late	O
-	O
stage	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
following	O
ROS	O
induction	O
,	O
a	O
family	O
of	O
pathogenic	O
brain	O
genes	O
that	O
promote	O
inflammatory	O
signalling	O
,	O
cellular	O
apoptosis	O
and	O
brain	O
cell	O
death	O
is	O
significantly	O
over	O
-	O
expressed	O
.	O

Iron-	O
and	O
aluminum	O
-	O
sulfate	O
together	O
,	O
at	O
nanomolar	O
concentrations	O
,	O
trigger	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
cultures	O
of	O
human	B
brain	O
cells	O
.	O

Induction	O
of	O
specific	O
micro	O
RNA	O
(	O
miRNA	O
)	O
species	O
by	O
ROS	O
-	O
generating	O
metal	O
sulfates	O
in	O
primary	O
human	B
brain	O
cells	O
.	O

The	O
rapid	O
and	O
exciting	O
pace	O
of	O
advances	O
in	O
glioblastoma	O
genetics	O
has	O
prompted	O
this	O
up	O
-	O
to	O
-	O
date	O
review	O
.	O

The	O
likely	O
impact	O
on	O
care	O
delivery	O
in	O
the	O
clinic	O
may	O
only	O
be	O
a	O
few	O
years	O
away	O
.	O

Within	O
the	O
last	O
few	O
years	O
,	O
high	O
-	O
throughput	O
efforts	O
such	O
as	O
The	O
Cancer	O
Genome	O
Atlas	O
and	O
a	O
massive	O
sequencing	O
project	O
have	O
yielded	O
novel	O
insights	O
and	O
classifications	O
of	O
this	O
dreaded	O
cancer	O
.	O

It	O
has	O
been	O
hoped	O
that	O
dissection	O
of	O
the	O
genetics	O
of	O
this	O
cancer	O
would	O
lead	O
to	O
more	O
targeted	O
and	O
effective	O
treatments	O
,	O
and	O
new	O
advances	O
may	O
finally	O
be	O
bringing	O
this	O
closer	O
to	O
fruition	O
.	O

Glioblastoma	O
genetics	O
:	O
in	O
rapid	O
flux	O
.	O

Glioblastoma	O
is	O
the	O
most	O
common	O
and	O
most	O
lethal	O
primary	O
brain	O
tumor	O
.	O

While	O
small	O
progress	O
has	O
been	O
made	O
in	O
treating	O
this	O
cancer	O
in	O
recent	O
years	O
,	O
glioblastoma	O
remains	O
largely	O
resistant	O
to	O
all	O
existing	O
therapies	O
.	O

Novel	O
animal	O
models	O
for	O
studying	O
complex	O
brain	O
disorders	O
:	O
BAC	O
-	O
driven	O
miRNA	O
-	O
mediated	O
in	O
vivo	O
silencing	O
of	O
gene	O
expression	O
.	O

In	O
schizophrenia	O
,	O
glutamic	O
acid	O
decarboxylase	O
1	O
(	O
GAD1	O
)	O
disturbances	O
are	O
robust	O
,	O
consistently	O
observed	O
,	O
cell	O
-	O
type	O
specific	O
and	O
represent	O
a	O
core	O
feature	O
of	O
the	O
disease	O
.	O

In	O
addition	O
,	O
neuropeptide	O
Y	O
(	O
NPY	O
)	O
,	O
which	O
is	O
a	O
phenotypic	O
marker	O
of	O
a	O
sub	O
-	O
population	O
of	O
GAD1-containing	O
interneurons	O
,	O
has	O
shown	O
reduced	O
expression	O
in	O
the	O
prefrontal	O
cortex	O
in	O
subjects	O
with	O
schizophrenia	O
,	O
suggesting	O
that	O
dysfunction	O
of	O
the	O
NPY+	O
cortical	O
interneuronal	O
sub	O
-	O
population	O
might	O
be	O
a	O
core	O
feature	O
of	O
this	O
devastating	O
disorder	O
.	O

However	O
,	O
modeling	O
gene	O
expression	O
disturbances	O
in	O
schizophrenia	O
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
has	O
been	O
extremely	O
challenging	O
.	O

To	O
more	O
closely	O
mimic	O
these	O
molecular	O
and	O
cellular	O
human	B
post	O
-	O
mortem	O
findings	O
,	O
we	O
generated	O
a	O
transgenic	B
mouse	I
in	O
which	O
we	O
downregulated	O
GAD1	O
mRNA	O
expression	O
specifically	O
in	O
NPY+	O
neurons	O
.	O

This	O
novel	O
,	O
cell	O
type	O
-	O
specific	O
in	O
vivo	O
system	O
for	O
reducing	O
gene	O
expression	O
uses	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
containing	O
the	O
NPY	O
promoter	O
-	O
enhancer	O
elements	O
,	O
the	O
reporter	O
molecule	O
(	O
eGFP	O
)	O
and	O
a	O
modified	O
intron	O
containing	O
a	O
synthetic	O
microRNA	O
(	O
miRNA	O
)	O
targeted	O
to	O
GAD1	O
.	O

The	O
animals	O
of	O
isogenic	O
strains	O
are	O
generated	O
rapidly	O
,	O
providing	O
a	O
new	O
tool	O
for	O
better	O
understanding	O
the	O
molecular	O
disturbances	O
in	O
the	O
GABAergic	O
system	O
observed	O
in	O
complex	O
neuropsychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

In	O
the	O
future	O
,	O
because	O
of	O
the	O
small	O
size	O
of	O
the	O
silencing	O
miRNAs	O
combined	O
with	O
our	O
BAC	O
strategy	O
,	O
this	O
method	O
may	O
be	O
modified	O
to	O
allow	O
generation	O
of	O
mice	B
with	O
simultaneous	O
silencing	O
of	O
multiple	O
genes	O
in	O
the	O
same	O
cells	O
with	O
a	O
single	O
construct	O
,	O
and	O
production	O
of	O
splice	O
-	O
variant	O
-	O
specific	O
knockdown	O
animals	O
.	O

Biomarkers	O
associated	O
with	O
metastasis	O
of	O
lung	O
cancer	O
to	O
brain	O
predict	O
patient	B
survival	O
.	O

This	O
research	O
involves	O
comprehensive	O
miRNA	O
expression	O
profiling	O
,	O
evaluation	O
of	O
normalisation	O
techniques	O
and	O
combination	O
of	O
miRNA	O
with	O
imaging	O
features	O
FDG	O
-	O
PET	O
/	O
CT	O
and	O
CT	O
Scan	O
.	O

We	O
combine	O
validated	O
miRNA	O
expression	O
values	O
with	O
imaging	O
features	O
to	O
classify	O
NSCLC	O
brain	O
mets	O
from	O
non	O
-	O
brain	O
mets	O
and	O
identify	O
possible	O
biomarkers	O
of	O
brain	O
mets	O
.	O

Generally	O
,	O
one	O
miRNA	O
is	O
predicted	O
to	O
regulate	O
several	O
hundred	O
genes	O
,	O
and	O
as	O
a	O
result	O
,	O
miRNAs	O
could	O
serve	O
as	O
a	O
better	O
classifier	O
than	O
gene	O
expression	O
.	O

MicroRNAs	O
influence	O
cell	O
physiology	O
;	O
alteration	O
in	O
miRNA	O
regulation	O
can	O
be	O
implicated	O
in	O
carcinogenesis	O
and	O
disease	O
progression	O
.	O

The	O
biomarkers	O
were	O
validated	O
on	O
an	O
independent	O
data	O
set	O
to	O
predict	O
potential	O
brain	O
mets	O
.	O

Through	O
various	O
experimental	O
approaches	O
,	O
we	O
validated	O
computational	O
predictions	O
and	O
demonstrated	O
that	O
miR-298	O
and	O
miR-328	O
recognize	O
specific	O
binding	O
sites	O
in	O
the	O
3'-UTR	O
of	O
BACE1	O
mRNA	O
and	O
exert	O
regulatory	O
effects	O
on	O
BACE1	O
protein	O
expression	O
in	O
cultured	O
neuronal	O
cells	O
.	O

Here	O
we	O
also	O
observed	O
a	O
loss	O
of	O
correlation	O
between	O
BACE1	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
hippocampus	O
of	O
a	O
mouse	B
model	O
of	O
AD	O
.	O
Consistent	O
with	O
an	O
impairment	O
of	O
miRNA	O
-	O
mediated	O
regulation	O
of	O
BACE1	O
expression	O
,	O
these	O
findings	O
prompted	O
us	O
to	O
investigate	O
the	O
regulatory	O
role	O
of	O
the	O
BACE1	O
3'-UTR	O
element	O
and	O
the	O
possible	O
involvement	O
of	O
specific	O
miRNAs	O
in	O
cultured	O
neuronal	O
(	O
N2a	O
)	O
and	O
fibroblastic	O
(	O
NIH	O
3T3	O
)	O
cells	O
.	O

Our	O
results	O
may	O
provide	O
the	O
molecular	O
basis	O
underlying	O
BACE1	O
deregulation	O
in	O
AD	O
and	O
offer	O
new	O
perspectives	O
on	O
the	O
etiology	O
of	O
this	O
neurological	O
disorder	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
key	O
regulatory	O
RNAs	O
known	O
to	O
repress	O
mRNA	O
translation	O
through	O
recognition	O
of	O
specific	O
binding	O
sites	O
located	O
mainly	O
in	O
their	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
.	O

MicroRNA-298	O
and	O
microRNA-328	O
regulate	O
expression	O
of	O
mouse	B
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
1	O
.	O

Intriguingly	O
,	O
previous	O
post	O
-	O
mortem	O
analyses	O
showed	O
higher	O
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
(	O
BACE	O
)	O
protein	O
,	O
but	O
not	O
mRNA	O
,	O
levels	O
in	O
the	O
brain	O
of	O
patients	B
that	O
suffered	O
from	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

Loss	O
of	O
specific	O
miRNA	O
control	O
of	O
gene	O
expression	O
is	O
thus	O
expected	O
to	O
underlie	O
serious	O
genetic	O
diseases	O
.	O

These	O
findings	O
reveal	O
a	O
significant	O
additional	O
mechanism	O
by	O
which	O
alpha	O
-	O
synuclein	O
is	O
regulated	O
and	O
point	O
toward	O
new	O
therapeutic	O
regimes	O
for	O
lowering	O
endogenous	O
alpha	O
-	O
synuclein	O
levels	O
in	O
patients	B
with	O
familial	O
or	O
sporadic	O
Parkinson	O
disease	O
.	O

Overexpression	O
of	O
mir-7	O
and	O
mir-153	O
significantly	O
reduces	O
endogenous	O
alpha	O
-	O
synuclein	O
levels	O
,	O
whereas	O
inhibition	O
of	O
mir-7	O
and	O
mir-153	O
enhances	O
translation	O
of	O
a	O
luciferase	O
construct	O
bearing	O
the	O
alpha	O
-	O
synuclein	O
3'-untranslated	O
region	O
in	O
primary	O
neurons	O
.	O

They	O
are	O
expressed	O
predominantly	O
in	O
the	O
brain	O
with	O
a	O
pattern	O
that	O
mirrors	O
synuclein	O
expression	O
in	O
different	O
tissues	O
as	O
well	O
as	O
during	O
neuronal	O
development	O
,	O
indicating	O
that	O
they	O
play	O
a	O
tuning	O
role	O
in	O
the	O
amount	O
of	O
alpha	O
-	O
synuclein	O
produced	O
.	O

These	O
microRNAs	O
bind	O
specifically	O
to	O
the	O
3'-untranslated	O
region	O
of	O
alpha	O
-	O
synuclein	O
and	O
down	O
-	O
regulate	O
its	O
mRNA	O
and	O
protein	O
levels	O
,	O
with	O
their	O
effect	O
being	O
additive	O
.	O

Here	O
,	O
two	O
microRNAs	O
,	O
namely	O
mir-7	O
and	O
mir-153	O
,	O
have	O
been	O
identified	O
to	O
regulate	O
alpha	O
-	O
synuclein	O
levels	O
post	O
-	O
transcriptionally	O
.	O

Genetic	O
and	O
biochemical	O
studies	O
have	O
established	O
a	O
central	O
role	O
for	O
alpha	O
-	O
synuclein	O
accumulation	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	O
disease	O
.	O

Post	O
-	O
transcriptional	O
regulation	O
of	O
alpha	O
-	O
synuclein	O
expression	O
by	O
mir-7	O
and	O
mir-153	O
.	O

Learning	O
,	O
retention	O
and	O
generalization	O
of	O
a	O
mirror	O
tracing	O
skill	O
in	O
Alzheimer	O
's	O
disease	O
.	O

The	O
present	O
study	O
examined	O
the	O
ability	O
of	O
12	O
patients	B
with	O
probable	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
12	O
age-	O
and	O
education	O
-	O
matched	O
normal	O
control	O
(	O
NC	O
)	O
subjects	O
to	O
learn	O
and	O
retain	O
the	O
visuomotor	O
skills	O
necessary	O
to	O
efficiently	O
trace	O
a	O
pattern	O
(	O
e.g.	O
,	O
a	O
4-	O
or	O
6-pointed	O
star	O
)	O
seen	O
only	O
in	O
mirror	O
-	O
reversed	O
view	O
.	O

Those	O
AD	O
(	O
N=6	O
)	O
and	O
NC	O
(	O
N=7	O
)	O
subjects	O
who	O
were	O
able	O
to	O
initially	O
perform	O
the	O
basic	O
mirror	O
tracing	O
task	O
did	O
not	O
differ	O
significantly	O
in	O
initial	O
level	O
of	O
performance	O
,	O
learning	O
over	O
trials	O
,	O
retention	O
of	O
the	O
skill	O
over	O
a	O
30-min	O
delay	O
interval	O
,	O
and	O
generalization	O
of	O
the	O
skill	O
to	O
a	O
new	O
figure	O
or	O
to	O
the	O
opposite	O
direction	O
of	O
tracing	O
.	O

The	O
AD	O
patients	B
who	O
were	O
unable	O
to	O
initially	O
perform	O
the	O
mirror	O
tracing	O
task	O
were	O
significantly	O
worse	O
than	O
those	O
who	O
could	O
perform	O
the	O
task	O
on	O
several	O
neuropsychological	O
measures	O
sensitive	O
to	O
deficits	O
in	O
problem	O
solving	O
and	O
executive	O
functions	O
,	O
but	O
not	O
on	O
tests	O
of	O
global	O
cognitive	O
decline	O
,	O
memory	O
,	O
language	O
,	O
or	O
visuoperceptual	O
functioning	O
.	O

These	O
results	O
indicate	O
that	O
acquisition	O
and	O
retention	O
of	O
a	O
complex	O
visuomotor	O
skill	O
can	O
proceed	O
normally	O
in	O
the	O
early	O
stages	O
of	O
AD	O
in	O
those	O
individuals	O
who	O
can	O
initially	O
perform	O
the	O
basic	O
task	O
,	O
and	O
that	O
inability	O
to	O
perform	O
the	O
basic	O
task	O
may	O
be	O
related	O
to	O
the	O
frontal	O
lobe	O
dysfunction	O
that	O
is	O
often	O
prominent	O
in	O
the	O
disorder	O
.	O

Thus	O
,	O
miR-206	O
slows	O
ALS	O
progression	O
by	O
sensing	O
motor	O
neuron	O
injury	O
and	O
promoting	O
the	O
compensatory	O
regeneration	O
of	O
neuromuscular	O
synapses	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
key	O
regulator	O
of	O
this	O
signaling	O
is	O
miR-206	O
,	O
a	O
skeletal	O
muscle	O
-	O
specific	O
microRNA	O
that	O
is	O
dramatically	O
induced	O
in	O
a	O
mouse	B
model	O
of	O
ALS	O
.	O

Mice	B
that	O
are	O
genetically	O
deficient	O
in	O
miR-206	O
form	O
normal	O
neuromuscular	O
synapses	O
during	O
development	O
,	O
but	O
deficiency	O
of	O
miR-206	O
in	O
the	O
ALS	O
mouse	B
model	O
accelerates	O
disease	O
progression	O
.	O

miR-206	O
is	O
required	O
for	O
efficient	O
regeneration	O
of	O
neuromuscular	O
synapses	O
after	O
acute	O
nerve	O
injury	O
,	O
which	O
probably	O
accounts	O
for	O
its	O
salutary	O
effects	O
in	O
ALS	O
.	O

miR-206	O
mediates	O
these	O
effects	O
at	O
least	O
in	O
part	O
through	O
histone	O
deacetylase	O
4	O
and	O
fibroblast	O
growth	O
factor	O
signaling	O
pathways	O
.	O

MicroRNA-206	O
delays	O
ALS	O
progression	O
and	O
promotes	O
regeneration	O
of	O
neuromuscular	O
synapses	O
in	O
mice	B
.	O

Amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
is	O
a	O
neurodegenerative	O
disease	O
characterized	O
by	O
loss	O
of	O
motor	O
neurons	O
,	O
denervation	O
of	O
target	O
muscles	O
,	O
muscle	O
atrophy	O
,	O
and	O
paralysis	O
.	O

Understanding	O
ALS	O
pathogenesis	O
may	O
require	O
a	O
fuller	O
understanding	O
of	O
the	O
bidirectional	O
signaling	O
between	O
motor	O
neurons	O
and	O
skeletal	O
muscle	O
fibers	O
at	O
neuromuscular	O
synapses	O
.	O

[	O
A	O
study	O
on	O
miRNA	O
alternation	O
after	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
using	O
microarray	O
technique	O
]	O
.	O

METHODS	O
:	O
PC12	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
H2O2	O
for	O
12	O
hours	O
,	O
and	O
then	O
the	O
cell	O
viabilities	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
cell	O
apoptosis	O
rates	O
were	O
assessed	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
screen	O
the	O
differentially	O
expressed	O
microRNAs	O
(	O
miRNA	O
)	O
between	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
and	O
normal	O
PC12	O
cells	O
with	O
microarray	O
chips	O
.	O

Of	O
the	O
46	O
miRNAs	O
in	O
the	O
H2O2	O
treated	O
groups	O
,	O
39	O
were	O
similar	O
to	O
that	O
of	O
the	O
control	O
group	O
and	O
6	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

CONCLUSION	O
:	O
Our	O
preliminary	O
data	O
may	O
provide	O
a	O
new	O
potential	O
foundation	O
for	O
further	O
study	O
of	O
pathogenesis	O
and	O
its	O
treatment	O
of	O
nerve	O
cell	O
apoptosis	O
caused	O
by	O
cerebral	O
ischemia	O
reperfusion	O
.	O

The	O
apoptosis	O
rates	O
for	O
them	O
were	O
2.6	O
%	O
,	O
5.2	O
%	O
,	O
7.2	O
%	O
,	O
10.4	O
%	O
,	O
16.6	O
%	O
,	O
and	O
72.2	O
%	O
accordingly	O
.	O

Expression	O
of	O
68	O
miRNAs	O
and	O
46	O
miRNAs	O
were	O
detected	O
in	O
both	O
control	O
group	O
and	O
the	O
H2O2	O
treated	O
groups	O
.	O

miRNAs	O
were	O
isolated	O
from	O
control	O
(	O
0	O
nmol	O
/	O
L	O
H2O2	O
)	O
and	O
H2O2	O
treated	O
(	O
at	O
concentrations	O
of	O
50	O
,	O
100	O
,	O
200	O
,	O
and	O
400	O
nmol	O
/	O
L	O
H2O2	O
,	O
respectively	O
)	O
groups	O
of	O
the	O
PC12	O
cells	O
,	O
respectively	O
,	O
and	O
were	O
then	O
detected	O
and	O
analyzed	O
by	O
microarray	O
chips	O
.	O

RESULTS	O
:	O
The	O
P12	O
cell	O
viabilities	O
in	O
control	O
and	O
H2O2	O
treated	O
group	O
were	O
(	O
92	O
+	O
/-	O
9.8	O
)	O
%	O
,	O
(	O
90	O
+	O
/-	O
14.70	O
)	O
%	O
,	O
(	O
80	O
+	O
/-	O
13.85	O
)	O
%	O
,	O
(	O
54	O
+	O
/-	O
12.23	O
)	O
%	O
,	O
and	O
(	O
22	O
+	O
/-	O
7.35	O
)	O
%	O
,	O
respectively	O
.	O

In	O
particular	O
,	O
SNP	O
rs12720208	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
was	O
linked	O
to	O
PD	O
-	O
risk	O
through	O
a	O
mechanism	O
that	O
would	O
implicate	O
a	O
differential	O
binding	O
to	O
microRNA-433	O
(	O
miR-433	O
)	O
.	O

The	O
reduction	O
of	O
the	O
affinity	O
of	O
miR-433	O
to	O
the	O
3	O
'	O
UTR	O
would	O
result	O
in	O
increased	O
FGF20	O
expression	O
and	O
upregulation	O
of	O
alpha	O
-	O
synuclein	O
,	O
which	O
could	O
in	O
turn	O
promote	O
dopaminergic	O
neurons	O
degeneration	O
.	O

FGF20	O
rs12720208	O
SNP	O
and	O
microRNA-433	O
variation	O
:	O
no	O
association	O
with	O
Parkinson	O
's	O
disease	O
in	O
Spanish	O
patients	B
.	O

DNA	O
variation	O
at	O
the	O
FGF20	O
gene	O
has	O
been	O
associated	O
with	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

In	O
conclusion	O
,	O
our	O
work	O
did	O
not	O
confirm	O
the	O
association	O
between	O
rs12720208	O
and	O
PD	O
,	O
or	O
an	O
effect	O
of	O
miR-433	O
variants	O
on	O
this	O
disease	O
.	O

None	O
of	O
the	O
patients	B
had	O
miR-433	O
variants	O
.	O

We	O
did	O
not	O
find	O
significant	O
differences	O
in	O
allele	O
and	O
genotype	O
frequencies	O
between	O
patients	B
and	O
controls	O
.	O

We	O
genotyped	O
the	O
rs12720208	O
SNP	O
in	O
a	O
total	O
of	O
512	O
PD	O
patients	B
and	O
258	O
healthy	O
controls	O
from	O
Spain	O
,	O
and	O
searched	O
for	O
miR-433	O
variants	O
in	O
the	O
patients	B
.	O

The	O
results	O
suggest	O
(	O
a	O
)	O
that	O
unless	O
specifically	O
stabilized	O
,	O
certain	O
brain	O
-	O
enriched	O
miRNAs	O
represent	O
a	O
rapidly	O
executed	O
signaling	O
system	O
employing	O
highly	O
transient	O
effectors	O
of	O
CNS	O
gene	O
expression	O
,	O
and	O
(	O
b	O
)	O
that	O
in	O
AD	O
temporal	O
lobe	O
neocortex	O
specific	O
brain	O
miRNAs	O
are	O
significantly	O
up	O
-	O
regulated	O
in	O
abundance	O
and	O
strongly	O
correlate	O
with	O
the	O
presence	O
of	O
AD	O
-	O
type	O
neuropatholgical	O
change	O
.	O

In	O
short	O
PMI	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
-affected	O
temporal	O
lobe	O
neocortex	O
,	O
miRNA-9	O
,	O
miRNA-125b	O
and	O
miRNA-146a	O
were	O
found	O
to	O
be	O
significantly	O
up	O
-	O
regulated	O
,	O
an	O
effect	O
that	O
was	O
not	O
seen	O
in	O
several	O
related	O
neurological	O
disorders	O
.	O

In	O
these	O
studies	O
,	O
miRNA	O
array	O
and	O
Northern	O
blot	O
based	O
tracking	O
of	O
specific	O
miRNA	O
abundances	O
and	O
decay	O
kinetics	O
in	O
human	B
neural	O
(	O
HN	O
)	O
cells	O
in	O
primary	O
culture	O
and	O
in	O
short	O
post	O
-	O
mortem	O
interval	O
(	O
PMI	O
,	O
approximately	O
1h	O
)	O
human	B
brain	O
tissues	O
showed	O
a	O
limited	O
stability	O
and	O
relatively	O
short	O
half	O
-	O
life	O
(	O
approximately	O
1	O
-	O
3.5h	O
)	O
for	O
specific	O
brain	O
-	O
enriched	O
miRNAs	O
.	O

Micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
mediated	O
regulation	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
complexity	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
emerging	O
as	O
a	O
critical	O
factor	O
in	O
the	O
control	O
of	O
CNS	O
-	O
specific	O
gene	O
expression	O
during	O
development	O
,	O
plasticity	O
,	O
aging	O
and	O
disease	O
.	O

Micro	O
-	O
RNA	O
abundance	O
and	O
stability	O
in	O
human	B
brain	O
:	O
specific	O
alterations	O
in	O
Alzheimer	O
's	O
disease	O
temporal	O
lobe	O
neocortex	O
.	O

Keystone	O
symposium	O
,	O
Neurodegenerative	O
Diseases	O
:	O
New	O
Molecular	O
Mechanisms	O
17	O
-	O
22	O
February	O
2009	O
.	O

Glioma	O
angiogenesis	O
:	O
Towards	O
novel	O
RNA	O
therapeutics	O
.	O

Brain	O
tumors	O
exhibit	O
marked	O
and	O
aberrant	O
blood	O
vessel	O
formation	O
indicating	O
angiogenic	O
endothelial	O
cells	O
as	O
a	O
potential	O
target	O
for	O
brain	O
tumor	O
treatment	O
.	O

The	O
brain	O
tumor	O
blood	O
vessels	O
are	O
used	O
for	O
nutrient	O
delivery	O
,	O
and	O
possibly	O
for	O
cancer	O
cell	O
migration	O
.	O

The	O
process	O
of	O
angiogenesis	O
is	O
complex	O
and	O
involves	O
multiple	O
players	O
.	O

The	O
current	O
angiogenesis	O
inhibitors	O
used	O
in	O
clinical	O
trials	O
mostly	O
target	O
single	O
angiogenic	O
proteins	O
and	O
so	O
far	O
show	O
limited	O
effects	O
on	O
tumor	O
growth	O
.	O

Besides	O
the	O
conventional	O
angiogenesis	O
inhibitors	O
,	O
RNA	O
-	O
based	O
inhibitors	O
such	O
as	O
small	O
-	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
are	O
being	O
analyzed	O
for	O
their	O
capacity	O
to	O
silence	O
the	O
message	O
of	O
proteins	O
involved	O
in	O
neovascularization	O
.	O

More	O
recently	O
,	O
a	O
new	O
family	O
of	O
non	O
-	O
coding	O
RNAs	O
,	O
named	O
angiomirs	O
[	O
microRNAs	O
(	O
miRNAs	O
)	O
involved	O
in	O
angiogenesis	O
]	O
has	O
emerged	O
.	O

These	O
small	O
RNAs	O
have	O
the	O
advantage	O
over	O
siRNAs	O
in	O
that	O
they	O
have	O
the	O
potential	O
of	O
silencing	O
multiple	O
messages	O
at	O
the	O
same	O
time	O
and	O
therefore	O
they	O
might	O
become	O
therapeutically	O
relevant	O
in	O
a	O
""""	O
one	O
-	O
hit	O
multiple	O
-	O
target	O
""""	O
context	O
against	O
brain	O
tumor	O
angiogenesis	O
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
emerging	O
technologies	O
in	O
anti	O
-	O
angiogenesis	O
emphasizing	O
on	O
RNA	O
-	O
based	O
therapeutics	O
.	O

Diseases	O
potentially	O
mediated	O
by	O
alterations	O
in	O
RNA	O
processes	O
include	O
tauopathies	O
,	O
myotonic	O
dystrophy	O
,	O
Alzheimer	O
disease	O
,	O
brain	O
cancer	O
,	O
and	O
many	O
others	O
.	O

Some	O
noncoding	O
RNAs	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
human	B
brain	O
diseases	O
.	O

Furthermore	O
,	O
there	O
is	O
poor	O
correlation	O
between	O
mRNA	O
levels	O
and	O
protein	O
levels	O
in	O
mammalian	O
cells	O
,	O
due	O
partly	O
to	O
complicated	O
post	O
-	O
transcriptional	O
regulation	O
by	O
hitherto	O
unknown	O
noncoding	O
RNAs	O
.	O

For	O
example	O
,	O
neurologic	O
illnesses	O
may	O
arise	O
because	O
of	O
perturbations	O
in	O
distinct	O
but	O
interrelated	O
tiers	O
of	O
RNA	O
-	O
based	O
genetic	O
regulation	O
:	O
pre	O
-	O
mRNA	O
splicing	O
;	O
nonsplicing	O
RNA	O
modifications	O
;	O
and	O
mRNA	O
translational	O
regulation	O
.	O

A	O
variety	O
of	O
unforeseen	O
complexities	O
have	O
been	O
identified	O
,	O
many	O
with	O
relevance	O
to	O
human	B
brain	O
disease	O
.	O

RNA	O
research	O
has	O
made	O
great	O
progress	O
in	O
recent	O
years	O
.	O

RNA	O
in	O
brain	O
disease	O
:	O
no	O
longer	O
just	O
""""	O
the	O
messenger	O
in	O
the	O
middle	O
""""	O
.	O

Here	O
we	O
present	O
an	O
overview	O
of	O
new	O
research	O
highlighting	O
functions	O
for	O
RNA	O
that	O
far	O
surpass	O
the	O
""""	O
messenger	O
in	O
the	O
middle	O
""""	O
role	O
and	O
that	O
identify	O
RNA	O
molecules	O
as	O
important	O
agents	O
in	O
the	O
human	B
brain	O
in	O
health	O
and	O
in	O
disease	O
states	O
.	O

RNA	O
editing	O
by	O
adenosine	O
deamination	O
is	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
regulation	O
of	O
gene	O
expression	O
and	O
is	O
particularly	O
widespread	O
in	O
mammals	O
.	O

Gene	O
regulation	O
through	O
RNA	O
editing	O
.	O

Here	O
,	O
I	O
am	O
reviewing	O
main	O
features	O
of	O
this	O
epigenetic	O
phenomenon	O
,	O
its	O
relevance	O
for	O
health	O
and	O
disease	O
,	O
as	O
well	O
as	O
potential	O
prospects	O
for	O
using	O
RNA	O
editing	O
as	O
a	O
therapeutic	O
tool	O
.	O

Widespread	O
A	O
-	O
to	O
-	O
I	O
modification	O
of	O
repeat	O
sequences	O
in	O
the	O
human	B
transcriptome	O
suggests	O
additional	O
roles	O
for	O
RNA	O
editing	O
and	O
links	O
it	O
to	O
other	O
processes	O
of	O
gene	O
regulation	O
,	O
such	O
as	O
RNA	O
splicing	O
as	O
well	O
as	O
siRNA	O
mediated	O
gene	O
silencing	O
and	O
miRNA	O
function	O
.	O

The	O
deficiency	O
or	O
misregulation	O
of	O
editing	O
has	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
neurological	O
diseases	O
,	O
such	O
as	O
epilepsy	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
depression	O
and	O
tumor	O
progression	O
.	O

Also	O
,	O
it	O
regulates	O
important	O
functional	O
properties	O
of	O
neurotransmitter	O
receptor	O
genes	O
in	O
the	O
central	O
nervous	O
system	O
by	O
changing	O
single	O
codons	O
in	O
pre	O
-	O
mRNA	O
.	O

A	O
-	O
to	O
-	O
I	O
RNA	O
editing	O
generates	O
transcriptome	O
and	O
proteome	O
diversity	O
allowing	O
organisms	O
to	O
produce	O
many	O
more	O
gene	O
products	O
and	O
functions	O
than	O
predicted	O
based	O
on	O
the	O
number	O
of	O
genes	O
within	O
their	O
genome	O
.	O

Gliomas	O
display	O
a	O
microRNA	O
expression	O
profile	O
reminiscent	O
of	O
neural	O
precursor	O
cells	O
.	O

Gliomas	O
express	O
many	O
genes	O
that	O
play	O
a	O
role	O
in	O
neural	O
precursor	O
cells	O
(	O
NPCs	O
)	O
,	O
but	O
no	O
direct	O
comparison	O
between	O
glioma	O
and	O
stem	O
cell	O
(	O
SC	O
)	O
gene	O
expression	O
profiles	O
has	O
been	O
performed	O
.	O

To	O
investigate	O
the	O
similarities	O
and	O
differences	O
between	O
gliomas	O
and	O
SCs	O
,	O
we	O
compared	O
the	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signatures	O
of	O
glial	O
tumors	O
,	O
embryonic	O
SCs	O
(	O
ESCs	O
)	O
,	O
NPCs	O
,	O
and	O
normal	O
adult	O
brains	O
from	O
both	O
human	B
and	O
mouse	B
tissues	O
.	O

We	O
demonstrated	O
that	O
both	O
human	B
gliomas	O
(	O
regardless	O
of	O
their	O
grade	O
)	O
and	O
methylcholanthrene	O
-	O
induced	O
mouse	B
glioma	O
shared	O
an	O
miRNA	O
expression	O
profile	O
that	O
is	O
reminiscent	O
of	O
NPCs	O
.	O

About	O
half	O
of	O
the	O
miRNAs	O
expressed	O
in	O
the	O
shared	O
profile	O
clustered	O
in	O
seven	O
genomic	O
regions	O
susceptible	O
to	O
genetic	O
/	O
epigenetic	O
alterations	O
in	O
various	O
cancers	O
.	O

These	O
clusters	O
comprised	O
the	O
miR17	O
family	O
,	O
mir183	O
-	O
182	O
,	O
and	O
the	O
SC	O
-	O
specific	O
clusters	O
mir367	O
-	O
302	O
and	O
mir371	O
-	O
373	O
,	O
which	O
are	O
upregulated	O
in	O
gliomas	O
,	O
ESCs	O
,	O
and	O
NPCs	O
.	O

The	O
bipartite	O
cluster	O
of	O
7	O
+	O
46	O
miRNAs	O
on	O
chromosome	O
14q32.31	O
,	O

which	O
might	O
represent	O
the	O
largest	O
tumor	O
suppressor	O
miRNA	O
cluster	O
,	O
was	O
downregulated	O
in	O
the	O
shared	O
expression	O
profile	O
.	O

This	O
study	O
provides	O
the	O
first	O
evidence	O
for	O
association	O
between	O
these	O
clusters	O
and	O
gliomas	O
.	O

Despite	O
the	O
broad	O
similarity	O
in	O
the	O
miRNA	O
expression	O
profiles	O
,	O
15	O
miRNAs	O
showed	O
disparate	O
expression	O
between	O
SC	O
and	O
gliomas	O
.	O

Ten	O
miRNAs	O
belong	O
to	O
the	O
2	O
SC	O
-	O
specific	O
clusters	O
and	O
the	O
remaining	O
(	O
mir135b	O
,	O
mir141	O
,	O
mir205	O
,	O
mir200C	O
,	O
and	O
mir301a	O
)	O
have	O
been	O
previously	O
shown	O
to	O
associate	O
with	O
malignancies	O
.	O

Our	O
finding	O
showed	O
that	O
all	O
gliomas	O
displayed	O
NPC	O
-	O
like	O
miRNA	O
signatures	O
,	O
which	O
may	O
have	O
implications	O
for	O
studies	O
of	O
glioma	O
origins	O
.	O

Furthermore	O
,	O
careful	O
study	O
of	O
the	O
15	O
miRNAs	O
that	O
differ	O
in	O
expression	O
between	O
SCs	O
and	O
gliomas	O
,	O
particularly	O
those	O
5	O
that	O
are	O
not	O
SC	O
-	O
specific	O
,	O
may	O
enhance	O
our	O
understanding	O
of	O
gliomagenesis	O
.	O

New	O
insights	O
into	O
the	O
roles	O
of	O
microRNAs	O
in	O
drug	O
addiction	O
and	O
neuroplasticity	O
.	O

In	O
this	O
review	O
,	O
the	O
aim	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
emerging	O
role	O
of	O
miRNAs	O
in	O
addiction	O
.	O

miRNAs	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
,	O
particularly	O
abundant	O
in	O
the	O
nervous	O
system	O
,	O
that	O
play	O
key	O
roles	O
as	O
regulatory	O
molecules	O
in	O
processes	O
such	O
as	O
neurogenesis	O
,	O
synapse	O
development	O
and	O
plasticity	O
in	O
the	O
brain	O
.	O

They	O
also	O
act	O
as	O
key	O
spatiotemporal	O
regulators	O
during	O
dendritic	O
morphogenesis	O
,	O
controlling	O
the	O
expression	O
of	O
hundreds	O
of	O
genes	O
involved	O
in	O
neuroplasticity	O
and	O
in	O
the	O
function	O
of	O
synapses	O
.	O

Recent	O
studies	O
have	O
identified	O
changes	O
of	O
several	O
specific	O
miRNA	O
expression	O
profiles	O
and	O
polymorphisms	O
affecting	O
the	O
interactions	O
between	O
miRNAs	O
and	O
their	O
targets	O
in	O
various	O
brain	O
disorders	O
,	O
including	O
addiction	O
:	O
miR-16	O
causes	O
adaptive	O
changes	O
in	O
production	O
of	O
the	O
serotonin	O
transporter	O
;	O
miR-133b	O
is	O
specifically	O
expressed	O
in	O
midbrain	O
dopaminergic	O
neurons	O
,	O
and	O
regulates	O
the	O
production	O
of	O
tyrosine	O
hydroxylase	O
and	O
the	O
dopamine	O
transporter	O
;	O
miR-212	O
affects	O
production	O
of	O
striatal	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
and	O
synaptic	O
plasticity	O
upon	O
cocaine	O
.	O

Clearly	O
,	O
specific	O
miRNAs	O
have	O
emerged	O
as	O
key	O
regulators	O
leading	O
to	O
addiction	O
,	O
and	O
could	O
serve	O
as	O
valuable	O
targets	O
for	O
more	O
efficient	O
therapies	O
.	O

ABSTRACT	O
:	O
Drug	O
addiction	O
is	O
a	O
major	O
public	O
health	O
issue	O
.	O

It	O
is	O
typically	O
a	O
multigenetic	O
brain	O
disorder	O
,	O
implying	O
combined	O
changes	O
of	O
expression	O
of	O
several	O
hundred	O
genes	O
.	O

Psychostimulants	O
(	O
such	O
as	O
cocaine	O
,	O
heroin	O
and	O
amphetamines	O
)	O
induce	O
strong	O
and	O
persistent	O
neuroadaptive	O
changes	O
through	O
a	O
surfeit	O
of	O
gene	O
regulatory	O
mechanisms	O
leading	O
to	O
addiction	O
.	O

Activity	O
-	O
dependent	O
synaptic	O
plasticity	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
,	O
known	O
as	O
the	O
'	O
reward	O
pathway	O
'	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
drug	O
dependence	O
.	O

